DECLARE (Dapagliflozin Effect on Cardiovascular Events-TIMI 58) is an AstraZeneca-sponsored, randomised, double-blinded, placebo-controlled, multicentre trial
designed to evaluate the effect of Forxiga compared with placebo on CV outcomes in adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV disease.
SOLO3 was a Phase III randomised, open-label, controlled, multicentre trial
to evaluate the efficacy and safety of Lynparza tablets following two or more prior lines of chemotherapy.
The Aga Khan University and the Shaukat Khanum Hospital are collaborating in a multicentre trial
with six other countries.
A recent multicentre trial
that covered 32 hospitals and 51 surgeons in the UK was reported in The Lancet.
Cochrane researchers updated the review of artesunate by adding a new large multicentre trial
of African children in 2010 to the existing 8 trials.
Efficacy and safety of oral alitretinoin (9-cis-retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
Ruzicka T, Lynde CW, Jemec GB et al.
The infamous Term Breech Trial, "Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial
" was published in The Lancet in October of 2000.
A large WHO multicentre trial
has suggested that fewer visits--a median of five per pregnancy compared with eight--can be introduced into clinical practice without causing adverse consequences to the woman or the baby.
The randomised, double-blind, placebo-controlled, multicentre trial
will enrol around 150 patients with gMG across sites in North America, Europe and Japan.
The product's ALTA-1L study is a global, ongoing, randomised, open-label, comparative and multicentre trial
that recruited 275 patients with ALK+ locally advanced or metastatic NSCLC who have not received prior treatment with an ALK inhibitor.
SOLO-1 is a Phase III randomised, double-blinded, placebo-controlled, multicentre trial
to assess the efficacy and safety of Lynparza tablets as first-line maintenance monotherapy compared with placebo, in patients with BRCAm advanced ovarian cancer.